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Mechanisms of Hamster Kidney Graft Rejection in the Rat 
H. Miyazawa, N. Murase, A.J. Demetris, K. Nakamura, K. Matsumoto, Q. Ye, R. Manez, S. Todo, 
and T.E. Starzl 
H AMSTER-to-rat transplantation has been widely 
used to study xenotransplantation between the rel-
atively closely related species. Recently, we developed the 
surgical procedure for kidney transplantation in this spe-
cies combination. This study describes mechanisms of 
hamster kidney graft rejection in the rat and the effect of 
different treatment protocols, including FK 506, cyclo-
phosphamide, and hamster organ perfusion, on graft sur-
vival. 
MATERIALS AND METHODS 
Animals 
Male Lewis rats (LEW, Harlan Sprague-Dawley, Indianapolis. 
Ind). weighing 200 to 300 g, and Golden Syrian hamsters (Charles 
River, Wilmington, Mass). weighing 100 to ISO g. were used as 
recipients and donors, respectively. 
Orthotopic Kidney Transplantation 
The left hamster kidney was isolated with the left renal artery on 
a segment of the aorta and the left renal vein with a cuff of inferior 
vena cava. The ureter was mobilized together with a small portion 
of the bladder. After donor heparinization (200 U), the graft was 
excised and perfused with 1 to 3 mL cold-lactated Ringer's 
solution via the aorta. Vascular reconstructions were by end-to-
side anastomoses of graft aorta to recipient infrarenal aorta and 
graft left renal vein to recipient inferior vena cava. Urinary tract 
was reconstructed by suturing recipient and donor bladders. 
Bilateral native nephrectomy was performed at the time of trans-
plantation. Graft rejection was defined by animal death. 
Liver or Kidney Perfusion 
In order to deplete preformed antihamster antibodies in the rat 
recipient, a hamster liver or kidney was temporarily connected to 
the recipient jugular vein and carotid artery by the cuff technique. 
Perfusion of either organ was initiated I hour before intra-
abdominal kidney transplantation and continued. for I.S to 2 
hours. 
Immunosuppressive Agents 
FK S06 (Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan) was 
dissolved in normal saline and given intramuscularly at doses of I 
to 2 mglkg per day. Cyclophosphamide (CP) was administered 
orally by gastric installation at a dose of 10 mglkg per day. 
Experimental groups and treatment regimens are shown in Fig I. 
Lymphocytotoxic Antibody Assay 
A complement-fixing lymphocytotoxic antibody assay was per-
formed using hamster lymphocytes as targets by Terasaki's meth-
od. I The lymphocytotoxic antibody titer was defined as the most 
diluted serum sample with greater than SO% cell lysis. 
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Fig 1, Animal survival after kidney transplantation from hamster 
to rat. (-0-) Group 1, no treatment (n=10); (-x-) group 
2, FK 506 2 mg/kg (n=11); (-0-) group 3, CP 10 mg/kg 
(n=6); (-e-) group 4, FK 506 1 mg/kg' + CP 10 mg/kg (days 
o to 6) (n=7); (-A-) group 5, liver perfusion + FK 506 1 
mglkg' + CP 10 mglkg (days 0 to 6) (n=9); (--0--) group 6. 
kidney perfusion + FK 5061 mg/kg' + CP 10 mg/kg (days 0 to 6) 
(n=8); (-_) group 7, FK 506 1 mg/kg' + CP 15 mg/kg (days 
3 to 1) (n=9) .• FK 506 was continued for 30 days, followed by 
every other day injection of 0.5 mg/kg. 
RESULTS 
Animal Survival 
Untreated recipients died between 5 and 6 days after 
transplantation (Fig I, group 1). FK 506 alone at a daily 
dose of2.0 mg/kg had no beneficial effect and animals died 
within 7 days (group 2). When used as a daily oral 
treatment, CP 10 mg/kg was more effective in prolonging 
graft survival. compared with FK 506, and median animal 
survival was 18.5 days (group 3). Combination treatment 
with FK 506 1.0 mg/kg per day and CP 10 mg/kg slightly 
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improved animal survival to 15 days (group 4). When 
performed antibodies were depleted before transplanta-
tion, better survival was obtained. Hamster liver perfusion 
with FK 506 and CP treatment significantly prolonged the 
kidney xenograft survival (group 5. median survival 34 
days). Better animal survival was also obtained after 
hamster kidney perfusion with FK 506 and CP treatment 
(group 6). Median animal survival was 48 days, and two of 
eight animals survived for more than 100 days. The best 
result was obtained when CP 15.0 mg/kg per day was 
started 3 days before grafting. Three of9 animals survived 
over 100 days (group 7). 
Antihamster Lymphocytotoxic Antibodies 
Antibody titer in untreated animals increased with time 
after transplantation and reached 211 to 213 when the 
animal died of rejection. This increase was slightly inhib-
ited by FK 506 treatment and completely abolished with 
CP 10 mg/kg administration. FK 506 and CP combination 
reduced the increase of the antihamster antibodies in all 
groups of animals in this study. 
Histopathology and Direct Immunofluorescence 
Untreated kidney grafts failed because of pure humoral 
rejection with numerous platelet-fibrin thrombi in the vas-
culature and widespread vascular and glomerular necrosis. 
No mononuclear infiltrates were seen. Intense IgM»IgG 
deposits in major arteries were seen as early as 1 hour after 
revascularization. The deposits increased with time and 
glomerular capillary loops and interstitium became IgM 
positive by 24 hours to 3 days. Liver or kidney perfusion, 
or cyclophosphamide pretreatment significantly decreased 
the IgM deposits in large arteries when examined 1 hour 
after grafting. 
DISCUSSION 
This study demonstrates that hamster kidney graft rejec-
tion is entirely mediated by humoral mechanisms in the 
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rat. Deposition of IgM»IgG antibodies to the endothe-
lium of main vessels was observed as early as I hour after 
revascularization and extended to glomerular capillary 
loops and interstitium with time. No mononuclear cell 
infiltrate was present. 
We have previously shown that long-term (> 100 days) 
hamster heart and liver xenograft survival in the rat was 
routinely obtained using FK 506 and a short induction 
course of antiproliferative drugs. 1 When the same treat-
ment strategy was applied to the kidney graft in this study. 
the results were not satisfactory and all animals died within 
30 days. Because of early antibody deposition and subse-
quent vascular damage seen in untreated animals. the 
effect of preformed antibody depletion on animal survival 
was also examined. Donor organ perfusion, which has 
been shown to mitigate hyperacute rejection in many 
studies,2 significantly improved hamster kidney graft sur-
vival in this study. Three-day pretreatment with CP was 
also effective to obtain better survival, suggesting the 
excellent effect of CP to suppress antibody production in 
this species combination. 
The critical role of preformed xenospecific natural anti-
bodies has been well demonstrated when grafts from 
widely separated species were hyperacutely rejected. In 
the hamster-to-rat combination, which is considered 
closely related xenotransplantation, the low levels of pre-
formed antibodies did not have a significant role for heart 
and liver grafting. 3 This study shows that kidney grafts 
were more susceptible to xenospecific antibody damage 
than heart and liver grafts and that treatment for preformed 
antibodies was necessary to obtain long-term survival. 
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